Amelioration of dystrophic epidermolysis bullosa pruriginosa symptoms with dupilumab: A case report

Yangbin Wang; Mingming Zhou; Li Zhang; Song Zheng; Yuxiao Hong; Xing-Hua Gao

doi:10.1111/dth.15130

Amelioration of dystrophic epidermolysis bullosa pruriginosa symptoms with dupilumab: A case report

Dermatol Ther. 2021 Nov;34(6):e15130. doi: 10.1111/dth.15130. Epub 2021 Sep 25.

Authors

Yangbin Wang^{1

2

3

4

5}, Mingming Zhou^{1

2

3

4

5}, Li Zhang^{1

2

3

4

5}, Song Zheng^{1

2

3

4

5}, Yuxiao Hong^{1

2

3

4

5}, Xing-Hua Gao^{1

2

3

4

5}

Affiliations

¹ Department of Dermatology, The First Hospital of China Medical University, Shenyang, China.
² NHC Key Laboratory of Immunodermatology (China Medical University), Shenyang, China.
³ Key Laboratory of Immunodermatology (China Medical University), Ministry of Education, Shenyang, China.
⁴ Key Laboratory of Immunodermatology, Shenyang, China.
⁵ Department of Education of Liaoning Province, Key Laboratory of Immunodermatology (China Medical University), Shenyang, China.

PMID: 34528352
DOI: 10.1111/dth.15130

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Collagen Type VII
Epidermolysis Bullosa Dystrophica* / diagnosis
Epidermolysis Bullosa Dystrophica* / drug therapy
Epidermolysis Bullosa*
Humans

Substances

Antibodies, Monoclonal, Humanized
Collagen Type VII
dupilumab

Supplementary concepts

Epidermolysis Bullosa Pruriginosa